Description

LEVERATAM 750 MG

Indications

LEVERATAM 750 MG is primarily indicated for the treatment of epilepsy, specifically for the management of partial-onset seizures in adults and children aged 4 years and older. It is also utilized as an adjunctive therapy in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. The medication is beneficial for patients who have not achieved adequate seizure control with other antiepileptic drugs, providing an alternative therapeutic option.

Mechanism of Action

The exact mechanism of action of LEVERATAM (Levetiracetam) is not fully understood. However, it is believed to modulate neurotransmitter release through binding to the synaptic vesicle protein SV2A, which is involved in the release of neurotransmitters. This action may help stabilize neuronal membranes and inhibit excessive neuronal firing, thereby reducing the frequency and severity of seizures. Additionally, LEVERATAM does not interact with traditional neurotransmitter systems such as GABA or glutamate, distinguishing it from many other antiepileptic medications.

Pharmacological Properties

LEVERATAM is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The bioavailability of LEVERATAM is approximately 100%, and it is not significantly affected by food intake. The drug is primarily eliminated through the kidneys, with about 66% of the administered dose excreted unchanged in the urine. The elimination half-life of LEVERATAM is approximately 7 to 8 hours in healthy adults, allowing for twice-daily dosing in most patients. The pharmacokinetics of LEVERATAM are linear, meaning that changes in dosage will result in proportional changes in drug concentration.

Contraindications

LEVERATAM is contraindicated in patients with a known hypersensitivity to Levetiracetam or any of its components. Caution is advised when prescribing this medication to individuals with renal impairment, as dosage adjustments may be necessary to prevent accumulation and potential toxicity. Additionally, it is essential to evaluate the risks versus benefits in pregnant or breastfeeding women, as the safety of LEVERATAM in these populations has not been fully established.

Side Effects

Common side effects associated with LEVERATAM include drowsiness, fatigue, dizziness, and headache. Some patients may experience behavioral changes such as irritability, aggression, or mood swings. Serious side effects, though less common, can include allergic reactions, severe skin rashes, and hematological abnormalities such as thrombocytopenia. Patients should be monitored for any unusual changes in mood or behavior, particularly during the initial phase of treatment or when doses are adjusted.

Dosage and Administration

The recommended starting dose of LEVERATAM for adults and children aged 16 years and older is typically 500 mg twice daily, which may be increased to a maximum dose of 1500 mg twice daily based on individual patient response and tolerability. For children aged 4 to 15 years, the initial dose is based on body weight, usually starting at 10 mg/kg/day, with gradual increases as needed. LEVERATAM can be taken with or without food, and it is essential to adhere to the prescribed dosing schedule to maintain therapeutic drug levels. If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose; in that case, the missed dose should be skipped.

Interactions

LEVERATAM has a relatively low potential for drug interactions compared to other antiepileptic medications. It is not significantly metabolized by cytochrome P450 enzymes, which reduces the likelihood of interactions with drugs that are substrates, inducers, or inhibitors of these enzymes. However, caution should be exercised when LEVERATAM is used concurrently with other central nervous system depressants, as they may enhance sedative effects. It is advisable to consult with a healthcare provider regarding all medications being taken to ensure safe and effective use.

Precautions

Patients should be closely monitored for signs of mood changes or behavioral issues, especially during the initiation of therapy or when doses are adjusted. LEVERATAM may increase the risk of suicidal thoughts or actions in some individuals, necessitating careful assessment of psychiatric history. Additionally, patients with a history of renal impairment should have their renal function evaluated regularly, as dosage adjustments may be required. It is also important for patients to avoid abrupt discontinuation of LEVERATAM, as this may lead to an increase in seizure frequency. A gradual tapering of the dose is recommended when discontinuing treatment.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of LEVERATAM in reducing seizure frequency in patients with epilepsy. In randomized controlled trials, LEVERATAM has shown significant reductions in partial-onset seizures when compared to placebo. Long-term studies have also indicated that LEVERATAM is effective as an adjunctive therapy, with many patients achieving improved seizure control and a favorable safety profile. The medication has been well-tolerated across diverse patient populations, including those with comorbid conditions.

Conclusion

LEVERATAM 750 MG is a valuable therapeutic option for patients with epilepsy, offering effective seizure control with a favorable safety profile. Its unique mechanism of action and low potential for drug interactions make it a suitable choice for many individuals, particularly those who have not responded adequately to other antiepileptic medications. As with any medication, careful monitoring and adherence to prescribed dosing are essential to optimize treatment outcomes and minimize potential side effects.